Bourbon, I find it hard to believe that biotech analysts don't understand ADXS's science. Although I am not doubting that those you spoke with did not understand it, I would imagine it is because they never looked into ADXS, rather than a lack of ability or desire to understand. But clearly there are other biotech analysts and investors that understand ADXS's science. I'm not sure what good it would do for analysts to wait for approval before figuring it out, as you suggest. Talk about missing the boat. I'm sure there is some of that. But there are obviously others who root out the next wave of innovation before approval. I'm also not sure I agree with your statement that a lack of approval is killing the stock price. There are plenty of companies that trade at high valuations way before approval, and some are even bought out. I am sure that the biotech investment community is largely aware of ADXS. What is inhibiting more investment is the extended attack on the pps, in my opinion, coupled with the present uncertainty about capital.
News 
Market Data 
Discover 
